Wave Life Sciences to discontinue development of suvodirsen for DMD
Category: #health  By Pankaj Singh  Date: 2019-12-17
  • share
  • Twitter
  • Facebook
  • LinkedIn

Wave Life Sciences to discontinue development of suvodirsen for DMD

The results from the clinical study rendered no change from baseline in dystrophin expression

Clinical stage genetic medicines company- Wave Life Sciences Ltd. has reportedly announced the halt of suvodirsen development for patients suffering from Duchenne Muscular Dystrophy who have been diagnosed with mutations amenable to exon 51 skipping, on the basis of the interim analysis during the Phase 1 open-label extension (OLE) trial.

Apparently, the results recorded no difference in dystrophin expression from baseline, when measured with western blot when given either 5 mg/kg or 3.5 mg/kg weekly doses of suvodirsen. Safety concerns or emerging safety signals were not observed.

Due to the aforementioned observations, the company has decided to discontinue the two suvodirsen trials with immediate effect, the Phase 2/3 DYSTANCE 51 trial and the OLE study. Patients are required to undergo a final follow-up visit; however, no further doses and muscle biopsies will be administered.

The analysis was derived from a multicenter suvodirsen OLE study in volunteers who had previously registered in the Phase 1 tolerability and safety study. Follow-up volunteers had enrolled in the OLE and were for the target doses of either 3.5 mg/kg or 5 mg/kg.

For the record, before the initial dosing in the OLE, a biopsy examination of the deltoid muscle was carried out and according to the data cut-off for the provisional analysis, the follow-up biopsies of the deltoid muscle were available for 27 of the 36 patients.

For the 5 mg/kg weekly infusion period, 10 patients obtained follow-up biopsies at twelve weeks while follow up muscle biopsies at twenty-two weeks was received by 9 patients. Eight patients got the twenty-two week follow up muscle biopsies within the 3.5 mg/kg weekly infusion arm. As a part of the interim analysis, biopsies from both the timepoints were analyzed.

About Suvodirsen

Wave Life Science announced the clinical development of suvodirsen in November 2017 and completed a Phase 1 safety and tolerability study by early 2019. It is an investigational stereopure oligonucleotide initially developed for the treatment of patients suffering from DMD who have genetic mutations amenable to exon 51 skipping.

 

Source Credits: https://ir.wavelifesciences.com/news-releases/news-release-details/wave-life-sciences-announces-discontinuation-suvodirsen

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh    

Pankaj Singh

With an experience as an insurance underwriter and a freelance writer under his belt, Pankaj Singh boasts of quite some expertise in the field of content creation. A qualified Post Graduate in Management, Pankaj has also completed a detailed course in Digital Marketin...

Read More

More News By Pankaj Singh

Genentech reveals submission of sBLA to FDA for Tecentriq-Avastin
Genentech reveals submission of sBLA to FDA for Tecentriq-Avastin
By Pankaj Singh

Genentech, Inc., a subsidiary of the Roche Group, has reportedly announced the completion of a sBLA (supplemental Biologics License Application) submission to the U.S. FDA (Food and Drug Administration) for Tecentriq ® (atezolizumab) in combinati...

FDA issues a cybersecurity warning for GE medical equipment
FDA issues a cybersecurity warning for GE medical equipment
By Pankaj Singh

The U.S. Food and Drug Administration, an agency within the U.S. Department of Health and Human Services, recently issued a safety communication informing patients, health care providers and facilities regarding the cybersecurity vulnerabilities...

French-Belgian biotech PDC*LINE bags USD 22.2M in a Series B funding
French-Belgian biotech PDC*LINE bags USD 22.2M in a Series B funding
By Pankaj Singh

A clinical stage biotechnology company, PDC*line Pharma, focused upon developing a new class of effective and scalable active immunotherapies for treating cancers, recently announced completion of a Series B round of funding. The company ha...